shutter

Amryt’s Lojuxta approved in Brazil to reduce cholesterol in homozygous familial hypercholesterolaemia patients

pharmafile | December 9, 2020 | News story | Research and Development, Sales and Marketing Amryt, Brazil, rare disease 

Brazil’s National Health Surveillance Agency (ANVISA) has moved to authorise Amryt’s Lojuxta (lomitapide) in the country as a treatment for the reduction of low-density lipoprotein cholesterol (LDL-C) in the rare condition homozygous familial hypercholesterolaemia (HoFH). 

The therapy is recommended as an adjunct to a low-fat diet and other lipid-lowering measures in adult HoFH patients, with or without low density lipoprotein (LDL) apheresis.

HoFH is a rare genetic disorder which affects the removal of LDL-C in the body, leading to levels in the blood which can be up to ten times higher than those without the condition. It is associated with the occurrence of “aggressive and premature” cardiovascular disease.

“We are pleased that ANVISA has recognised the significant unmet medical need of patients in Brazil suffering from HoFH and have approved marketing authorisation for Lojuxta to treat adults with this condition,” remarked Dr Joe Wiley, Chief Executive Officer of Amryt. “Today’s news is another milestone in executing our strategy to make Lojuxta available to HoFH patients in need globally.”

Matt Fellows

Related Content

FDA approves first ever treatment for rare CHAPLE disease

The US Food and Drug Administration (FDA) has approved Regeneron’s Veopoz (pozelimab), a new treatment …

genes

AstraZeneca’s Alexion partners with Pfizer for rare disease therapies

Alexion, AstraZeneca’s Rare Disease division, has announced that it has entered a definitive purchase and …

Kintor’s COVID-19 treatment reduces mortality by 92%

Kintor Pharmaceutical’s Proxalutamide treatment has been proven to reduce risk of mortality from COVID-19 by …

Latest content